Head and Neck Squamous Cell Carcinoma CPG Mini Module - Risks and Benefits of Immunotherapy Combination Therapies to Treat Oligometastatic Disease
The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.
Panelists Dan P. Zandberg, MD - UPMC Hillman Cancer Center, Ezra Cohen, MD, FRCPSC, FASCO - UC of San Diego, and Andrew G. Sikora, MD, PhD - University of Texas MD Anderson Cancer Center compare the risks and benefits of combining local therapy with systemic immunotherapy to the risks and benefits local therapy alone to treat recurrent head and neck squamous cell carcinoma (HNSCC) in patients who test positive for HPV. Insights into the sequencing of immunotherapy with stereotactic body radiotherapy (SBRT) to treat oligometastatic disease is also discussed. The discussion ends with the panelists' insight on emerging immunotherapy combinations, intratumoral treatments, and the future of combination therapy for HNSCC.
Run time: Approximately 13 minutes
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021).
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.